Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a biotechnology company with a positive outlook due to strong progress in their givastomig and VIS-101 programs, which have shown promising data in clinical trials and have the potential to be differentiated assets in their respective markets. Their current financials are stable, with a strong cash position expected to support operations through 2028, and their management team has a clear focus on research and development to drive growth in the long term. Risks to achieving their potential include regulatory and clinical development challenges, but the company's diversified pipeline and broad patient coverage reduces reliance on precise biomarker testing.

Bears say

NovaBridge Biosciences is operating in a highly competitive and complex biotechnology landscape, facing numerous challenges to bring their innovative drug pipeline to market and generate sustainable revenue. Though their potential in-class CLDN18.2 bispecific antibody has shown promising results in both high and low CLDN18.2 expressing patients, KOLs have reported high discontinuation rates and challenges with adoption in real-world settings for similar targeting strategies, highlighting potential risks and headwinds for the company's success. Additionally, their projected financials and valuation are based on optimistic assumptions and may not accurately reflect the challenges and risks that the company will face.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.